Two-year Assessment of the Efficacy and Safety of Ocrelizumab in Switching Patients from Other Disease Modifying Therapies


TERZİ M., BOZ C., DEMİR C. F., ÇİLİNGİR V., HELVACI E. M.

Journal of Multiple Sclerosis, 2023 (Peer-Reviewed Journal)